## Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study

Amanda J Cross,<sup>1\*</sup> Emma C Robbins,<sup>1</sup> Kevin Pack,<sup>1</sup> Iain Stenson,<sup>1</sup> Paula L Kirby,<sup>1</sup> Bhavita Patel,<sup>1</sup> Matthew D Rutter,<sup>2,3</sup> Andrew M Veitch,<sup>4</sup> Brian P Saunders,<sup>5</sup> Matthew Little,<sup>6</sup> Alastair Gray,<sup>6</sup> Stephen W Duffy<sup>7</sup> and Kate Wooldrage<sup>1</sup>

- <sup>2</sup>Department of Gastroenterology, University Hospital of North Tees, Stockton-on-Tees, UK
- <sup>3</sup>Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK <sup>4</sup>Department of Gastroenterology, New Cross Hospital, Wolverhampton, UK
- <sup>5</sup>Wolfson Unit for Endoscopy, St Mark's Hospital, London, UK
- <sup>6</sup>Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- <sup>7</sup>Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK

\*Corresponding author amanda.cross1@imperial.ac.uk

**Declared competing interests of authors:** Amanda J Cross receives funding from Cancer Research UK (London, UK) (Population Research Committee – Programme Award C53889/A25004). Matthew D Rutter reports speaker honoraria from Swiss SCWeb AG (Lucerne, Switzerland) and PENTAX Medical (Tokyo, Japan), a grant from Olympus Corporation (Tokyo, Japan) and consultancy fees from Norgine BV (Amsterdam, the Netherlands) outside the submitted work. Brian P Saunders reports research grants, personal fees and non-financial support from Olympus Corporation, personal fees from Boston Scientific Corporation (Marlborough, MA, USA), Creo Medical Group plc (Chepstow, UK) and Norgine BV, a patent and royalty agreement with Diagmed Healthcare Ltd (Thirsk, UK) and Creo Medical Group plc, and equity in Creo Medical Group plc outside the submitted work. Alastair Gray is partly funded by the National Institute for Health and Care Research Biomedical Research Centre (Oxford, UK) and is a member of the UK National Screening Committee (London, UK) (2015–present).

Published May 2022 DOI: 10.3310/OLUE3796

<sup>&</sup>lt;sup>1</sup>Cancer Screening and Prevention Research Group, Department of Surgery and Cancer, Imperial College London, London, UK

# **Plain English summary**

Colonoscopy surveillance following adenoma removal Health Technology Assessment 2022; Vol. 26: No. 26 DOI: 10.3310/OLUE3796

NIHR Journals Library www.journalslibrary.nihr.ac.uk

# **Plain English summary**

B owel cancers develop from polyps, also called adenomas, which are growths on the lining of the bowel. Removal of adenomas, therefore, helps prevent bowel cancer. Adenomas can be detected and removed during colonoscopy, when a thin tube with a camera on one end is used to examine the bowel lining. In the UK, patients with adenomas are divided into three risk groups. Low-risk patients (i.e. those with one or two adenomas that are < 10 mm in size) are thought to be unlikely to develop bowel cancer after adenoma removal and follow-up colonoscopy is not recommended in this group. Intermediate-risk patients (i.e. those with three or four adenomas that are < 10 mm in size, or one or two adenomas with at least one  $\geq$  10 mm in size) are recommended to have another colonoscopy 3 years after adenoma removal. High-risk patients (i.e. those with five or more adenomas that are < 10 mm in size, or three or more adenomas with at least one  $\geq$  10 mm in size) are recommended to have another colonoscopy after 1 year and then usually again after 3 years.

The number of follow-up colonoscopies carried out is stretching health-care resources and each procedure carries a small risk of complications for patients. It is possible that too many follow-up colonoscopies are being carried out. This study aimed to determine which patients require follow-up colonoscopies and how many are required to detect adenomas and prevent bowel cancer, while also being resource-efficient, cost-effective and not exposing patients to unnecessary risks.

The study used data from 17 hospitals and cancer registries in the UK. In each risk group, one follow-up colonoscopy after adenoma removal was associated with a 40–50% reduction in bowel cancer risk. However, even without any follow-up, bowel cancer risk was no higher in some low- and intermediate-risk patients than in the general population. These patients may not need as many follow-up colonoscopies as recommended. In the case of higher-risk patients, who even after adenoma removal have a higher bowel cancer risk than the general population, follow-up colonoscopies are necessary and cost-effective.

### **Health Technology Assessment**

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

#### **HTA programme**

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

#### **This report**

The research reported in this issue of the journal was funded by the HTA programme as project number 15/80/13. The contractual start date was in March 2017. The draft report began editorial review in March 2020 and was accepted for publication in June 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the NHS, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Copyright © 2022 Cross *et al.* This work was produced by Cross *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

### NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

### NIHR Journals Library Editors

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Senior Adviser, Wessex Institute, University of Southampton, UK

Dr Catriona McDaid Reader in Trials, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk